Industry Research Reports

Home > Reports > Medical Care > Global Antibody and Recombinant Protein CDMO Market Insights, Forecast to 2030

Global Antibody and Recombinant Protein CDMO Market Insights, Forecast to 2030

Industry: Medical Care

Published Date: 2024-04-12

Pages: 129 Pages

Report ld: 2918792

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Antibody and Recombinant Protein CDMO Market Size(US$)

CAGR 2024-2030

Market Size,2030

USD 83,480

Million

Market Snapshot

Market Size in 2024 (Value)

US$ 55,630 million

Market Forecast in 2030(Value)

US$ 83,480 million

CAGR

Years Considered

2019-2030

Base Year

2024

Forecast Period

2024-2030

Source: Secondary research, interviews with experts, and QYResearch analysis

Market Analysis and Insights: Global Antibody and Recombinant Protein CDMO Market

The global Antibody and Recombinant Protein CDMO market is projected to grow from US$ 55630 million in 2024 to US$ 83480 million by 2030, at a Compound Annual Growth Rate (CAGR) of 7.0% during the forecast period.

The US & Canada market for Antibody and Recombinant Protein CDMO is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Antibody and Recombinant Protein CDMO is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The Europe market for Antibody and Recombinant Protein CDMO is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The global key companies of Antibody and Recombinant Protein CDMO include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck and Hangzhou Hs-biopharm, etc. In 2023, the global top five players had a share approximately % in terms of revenue.

Antibody and Recombinant Protein CDMO is widely used in various fields, such as Pharmaceutical Company, Biotechnology Company and Generic Company,, etc. Pharmaceutical Company provides greatest supports to the Antibody and Recombinant Protein CDMO industry development. In 2023, global % revenue of Antibody and Recombinant Protein CDMO went into Pharmaceutical Company filed and the proportion will reach to % in 2030.

Report Covers:

This report presents an overview of global market for Antibody and Recombinant Protein CDMO market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Antibody and Recombinant Protein CDMO, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antibody and Recombinant Protein CDMO, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antibody and Recombinant Protein CDMO revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Antibody and Recombinant Protein CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Antibody and Recombinant Protein CDMO revenue, projected growth trends, production technology, application and end-user industry.

MARKET SEGMENTATION

By Company

Batavia Biosciences
Grifols
Cerbios-Pharma SA
HALIX
Biovian Oy
Catalent
Goodwin Biotechnology
Merck
Hangzhou Hs-biopharm
Wuxibiologics
Bioinnobio
Thousand Oaks Biopharmaceuticals
Eurogentec
HJB
Bibo Pharma
MabPlex International
Genscriptprobio
Vetter
Etinpro (Beijing) Co
Boehringer Ingelheim BioXcellence
Lonza
3SBio Inc
Porton

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Antibody CDMO
Recombinant Protein CDMO

Segment by Application

Pharmaceutical Company
Biotechnology Company
Generic Company

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Antibody CDMO

1.2.3 Recombinant Protein CDMO

1.3 Market by Application

1.3.1 Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Pharmaceutical Company

1.3.3 Biotechnology Company

1.3.4 Generic Company

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Antibody and Recombinant Protein CDMO Market Perspective (2019-2030)

2.2 Global Antibody and Recombinant Protein CDMO Growth Trends by Region

2.2.1 Antibody and Recombinant Protein CDMO Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Antibody and Recombinant Protein CDMO Historic Market Size by Region (2019-2024)

2.2.3 Antibody and Recombinant Protein CDMO Forecasted Market Size by Region (2025-2030)

2.3 Antibody and Recombinant Protein CDMO Market Dynamics

2.3.1 Antibody and Recombinant Protein CDMO Industry Trends

2.3.2 Antibody and Recombinant Protein CDMO Market Drivers

2.3.3 Antibody and Recombinant Protein CDMO Market Challenges

2.3.4 Antibody and Recombinant Protein CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Antibody and Recombinant Protein CDMO by Players

3.1.1 Global Antibody and Recombinant Protein CDMO Revenue by Players (2019-2024)

3.1.2 Global Antibody and Recombinant Protein CDMO Revenue Market Share by Players (2019-2024)

3.2 Global Antibody and Recombinant Protein CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Antibody and Recombinant Protein CDMO, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global Antibody and Recombinant Protein CDMO Market Concentration Ratio

3.4.1 Global Antibody and Recombinant Protein CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Antibody and Recombinant Protein CDMO Revenue in 2023

3.5 Global Key Players of Antibody and Recombinant Protein CDMO Head office and Area Served

3.6 Global Key Players of Antibody and Recombinant Protein CDMO, Product and Application

3.7 Global Key Players of Antibody and Recombinant Protein CDMO, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Antibody and Recombinant Protein CDMO Breakdown Data by Type

4.1 Global Antibody and Recombinant Protein CDMO Historic Market Size by Type (2019-2024)

4.2 Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Type (2025-2030)

5 Antibody and Recombinant Protein CDMO Breakdown Data by Application

5.1 Global Antibody and Recombinant Protein CDMO Historic Market Size by Application (2019-2024)

5.2 Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Antibody and Recombinant Protein CDMO Market Size (2019-2030)

6.2 North America Antibody and Recombinant Protein CDMO Market Size by Type

6.2.1 North America Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024)

6.2.2 North America Antibody and Recombinant Protein CDMO Market Size by Type (2025-2030)

6.2.3 North America Antibody and Recombinant Protein CDMO Market Share by Type (2019-2030)

6.3 North America Antibody and Recombinant Protein CDMO Market Size by Application

6.3.1 North America Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024)

6.3.2 North America Antibody and Recombinant Protein CDMO Market Size by Application (2025-2030)

6.3.3 North America Antibody and Recombinant Protein CDMO Market Share by Application (2019-2030)

6.4 North America Antibody and Recombinant Protein CDMO Market Size by Country

6.4.1 North America Antibody and Recombinant Protein CDMO Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024)

6.4.3 North America Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030)

6.4.4 U.S.

6.4.5 Canada

7 Europe

7.1 Europe Antibody and Recombinant Protein CDMO Market Size (2019-2030)

7.2 Europe Antibody and Recombinant Protein CDMO Market Size by Type

7.2.1 Europe Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024)

7.2.2 Europe Antibody and Recombinant Protein CDMO Market Size by Type (2025-2030)

7.2.3 Europe Antibody and Recombinant Protein CDMO Market Share by Type (2019-2030)

7.3 Europe Antibody and Recombinant Protein CDMO Market Size by Application

7.3.1 Europe Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024)

7.3.2 Europe Antibody and Recombinant Protein CDMO Market Size by Application (2025-2030)

7.3.3 Europe Antibody and Recombinant Protein CDMO Market Share by Application (2019-2030)

7.4 Europe Antibody and Recombinant Protein CDMO Market Size by Country

7.4.1 Europe Antibody and Recombinant Protein CDMO Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024)

7.4.3 Europe Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Antibody and Recombinant Protein CDMO Market Size (2019-2030)

8.2 China Antibody and Recombinant Protein CDMO Market Size by Type

8.2.1 China Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024)

8.2.2 China Antibody and Recombinant Protein CDMO Market Size by Type (2025-2030)

8.2.3 China Antibody and Recombinant Protein CDMO Market Share by Type (2019-2030)

8.3 China Antibody and Recombinant Protein CDMO Market Size by Application

8.3.1 China Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024)

8.3.2 China Antibody and Recombinant Protein CDMO Market Size by Application (2025-2030)

8.3.3 China Antibody and Recombinant Protein CDMO Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Antibody and Recombinant Protein CDMO Market Size (2019-2030)

9.2 Asia Antibody and Recombinant Protein CDMO Market Size by Type

9.2.1 Asia Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024)

9.2.2 Asia Antibody and Recombinant Protein CDMO Market Size by Type (2025-2030)

9.2.3 Asia Antibody and Recombinant Protein CDMO Market Share by Type (2019-2030)

9.3 Asia Antibody and Recombinant Protein CDMO Market Size by Application

9.3.1 Asia Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024)

9.3.2 Asia Antibody and Recombinant Protein CDMO Market Size by Application (2025-2030)

9.3.3 Asia Antibody and Recombinant Protein CDMO Market Share by Application (2019-2030)

9.4 Asia Antibody and Recombinant Protein CDMO Market Size by Region

9.4.1 Asia Antibody and Recombinant Protein CDMO Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia Antibody and Recombinant Protein CDMO Market Size by Region (2019-2024)

9.4.3 Asia Antibody and Recombinant Protein CDMO Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Type

10.2.1 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Application

10.3.1 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Country

10.4.1 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 Batavia Biosciences

11.1.1 Batavia Biosciences Company Details

11.1.2 Batavia Biosciences Business Overview

11.1.3 Batavia Biosciences Antibody and Recombinant Protein CDMO Introduction

11.1.4 Batavia Biosciences Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.1.5 Batavia Biosciences Recent Developments

11.2 Grifols

11.2.1 Grifols Company Details

11.2.2 Grifols Business Overview

11.2.3 Grifols Antibody and Recombinant Protein CDMO Introduction

11.2.4 Grifols Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.2.5 Grifols Recent Developments

11.3 Cerbios-Pharma SA

11.3.1 Cerbios-Pharma SA Company Details

11.3.2 Cerbios-Pharma SA Business Overview

11.3.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Introduction

11.3.4 Cerbios-Pharma SA Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.3.5 Cerbios-Pharma SA Recent Developments

11.4 HALIX

11.4.1 HALIX Company Details

11.4.2 HALIX Business Overview

11.4.3 HALIX Antibody and Recombinant Protein CDMO Introduction

11.4.4 HALIX Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.4.5 HALIX Recent Developments

11.5 Biovian Oy

11.5.1 Biovian Oy Company Details

11.5.2 Biovian Oy Business Overview

11.5.3 Biovian Oy Antibody and Recombinant Protein CDMO Introduction

11.5.4 Biovian Oy Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.5.5 Biovian Oy Recent Developments

11.6 Catalent

11.6.1 Catalent Company Details

11.6.2 Catalent Business Overview

11.6.3 Catalent Antibody and Recombinant Protein CDMO Introduction

11.6.4 Catalent Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.6.5 Catalent Recent Developments

11.7 Goodwin Biotechnology

11.7.1 Goodwin Biotechnology Company Details

11.7.2 Goodwin Biotechnology Business Overview

11.7.3 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Introduction

11.7.4 Goodwin Biotechnology Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.7.5 Goodwin Biotechnology Recent Developments

11.8 Merck

11.8.1 Merck Company Details

11.8.2 Merck Business Overview

11.8.3 Merck Antibody and Recombinant Protein CDMO Introduction

11.8.4 Merck Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.8.5 Merck Recent Developments

11.9 Hangzhou Hs-biopharm

11.9.1 Hangzhou Hs-biopharm Company Details

11.9.2 Hangzhou Hs-biopharm Business Overview

11.9.3 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Introduction

11.9.4 Hangzhou Hs-biopharm Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.9.5 Hangzhou Hs-biopharm Recent Developments

11.10 Wuxibiologics

11.10.1 Wuxibiologics Company Details

11.10.2 Wuxibiologics Business Overview

11.10.3 Wuxibiologics Antibody and Recombinant Protein CDMO Introduction

11.10.4 Wuxibiologics Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.10.5 Wuxibiologics Recent Developments

11.11 Bioinnobio

11.11.1 Bioinnobio Company Details

11.11.2 Bioinnobio Business Overview

11.11.3 Bioinnobio Antibody and Recombinant Protein CDMO Introduction

11.11.4 Bioinnobio Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.11.5 Bioinnobio Recent Developments

11.12 Thousand Oaks Biopharmaceuticals

11.12.1 Thousand Oaks Biopharmaceuticals Company Details

11.12.2 Thousand Oaks Biopharmaceuticals Business Overview

11.12.3 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Introduction

11.12.4 Thousand Oaks Biopharmaceuticals Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.12.5 Thousand Oaks Biopharmaceuticals Recent Developments

11.13 Eurogentec

11.13.1 Eurogentec Company Details

11.13.2 Eurogentec Business Overview

11.13.3 Eurogentec Antibody and Recombinant Protein CDMO Introduction

11.13.4 Eurogentec Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.13.5 Eurogentec Recent Developments

11.14 HJB

11.14.1 HJB Company Details

11.14.2 HJB Business Overview

11.14.3 HJB Antibody and Recombinant Protein CDMO Introduction

11.14.4 HJB Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.14.5 HJB Recent Developments

11.15 Bibo Pharma

11.15.1 Bibo Pharma Company Details

11.15.2 Bibo Pharma Business Overview

11.15.3 Bibo Pharma Antibody and Recombinant Protein CDMO Introduction

11.15.4 Bibo Pharma Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.15.5 Bibo Pharma Recent Developments

11.16 MabPlex International

11.16.1 MabPlex International Company Details

11.16.2 MabPlex International Business Overview

11.16.3 MabPlex International Antibody and Recombinant Protein CDMO Introduction

11.16.4 MabPlex International Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.16.5 MabPlex International Recent Developments

11.17 Genscriptprobio

11.17.1 Genscriptprobio Company Details

11.17.2 Genscriptprobio Business Overview

11.17.3 Genscriptprobio Antibody and Recombinant Protein CDMO Introduction

11.17.4 Genscriptprobio Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.17.5 Genscriptprobio Recent Developments

11.18 Vetter

11.18.1 Vetter Company Details

11.18.2 Vetter Business Overview

11.18.3 Vetter Antibody and Recombinant Protein CDMO Introduction

11.18.4 Vetter Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.18.5 Vetter Recent Developments

11.19 Etinpro (Beijing) Co

11.19.1 Etinpro (Beijing) Co Company Details

11.19.2 Etinpro (Beijing) Co Business Overview

11.19.3 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Introduction

11.19.4 Etinpro (Beijing) Co Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.19.5 Etinpro (Beijing) Co Recent Developments

11.20 Boehringer Ingelheim BioXcellence

11.20.1 Boehringer Ingelheim BioXcellence Company Details

11.20.2 Boehringer Ingelheim BioXcellence Business Overview

11.20.3 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Introduction

11.20.4 Boehringer Ingelheim BioXcellence Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.20.5 Boehringer Ingelheim BioXcellence Recent Developments

11.21 Lonza

11.21.1 Lonza Company Details

11.21.2 Lonza Business Overview

11.21.3 Lonza Antibody and Recombinant Protein CDMO Introduction

11.21.4 Lonza Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.21.5 Lonza Recent Developments

11.22 3SBio Inc

11.22.1 3SBio Inc Company Details

11.22.2 3SBio Inc Business Overview

11.22.3 3SBio Inc Antibody and Recombinant Protein CDMO Introduction

11.22.4 3SBio Inc Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.22.5 3SBio Inc Recent Developments

11.23 Porton

11.23.1 Porton Company Details

11.23.2 Porton Business Overview

11.23.3 Porton Antibody and Recombinant Protein CDMO Introduction

11.23.4 Porton Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)

11.23.5 Porton Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of Antibody CDMO

Table 3. Key Players of Recombinant Protein CDMO

Table 4. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 5. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Antibody and Recombinant Protein CDMO Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Antibody and Recombinant Protein CDMO Market Share by Region (2019-2024)

Table 8. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Antibody and Recombinant Protein CDMO Market Share by Region (2025-2030)

Table 10. Antibody and Recombinant Protein CDMO Market Trends

Table 11. Antibody and Recombinant Protein CDMO Market Drivers

Table 12. Antibody and Recombinant Protein CDMO Market Challenges

Table 13. Antibody and Recombinant Protein CDMO Market Restraints

Table 14. Global Antibody and Recombinant Protein CDMO Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Antibody and Recombinant Protein CDMO Revenue Share by Players (2019-2024)

Table 16. Global Top Antibody and Recombinant Protein CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody and Recombinant Protein CDMO as of 2023)

Table 17. Global Antibody and Recombinant Protein CDMO Industry Ranking 2022 VS 2023 VS 2024

Table 18. Global 5 Largest Players Market Share by Antibody and Recombinant Protein CDMO Revenue (CR5 and HHI) & (2019-2024)

Table 19. Global Key Players of Antibody and Recombinant Protein CDMO, Headquarters and Area Served

Table 20. Global Key Players of Antibody and Recombinant Protein CDMO, Product and Application

Table 21. Global Key Players of Antibody and Recombinant Protein CDMO, Product and Application

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Type (2019-2024)

Table 25. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Type (2025-2030)

Table 27. Global Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Antibody and Recombinant Protein CDMO Revenue Share by Application (2019-2024)

Table 29. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Antibody and Recombinant Protein CDMO Revenue Share by Application (2025-2030)

Table 31. North America Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024) & (US$ Million)

Table 32. North America Antibody and Recombinant Protein CDMO Market Size by Type (2025-2030) & (US$ Million)

Table 33. North America Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024) & (US$ Million)

Table 34. North America Antibody and Recombinant Protein CDMO Market Size by Application (2025-2030) & (US$ Million)

Table 35. North America Antibody and Recombinant Protein CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. North America Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024) & (US$ Million)

Table 37. North America Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030) & (US$ Million)

Table 38. Europe Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024) & (US$ Million)

Table 39. Europe Antibody and Recombinant Protein CDMO Market Size by Type (2025-2030) & (US$ Million)

Table 40. Europe Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024) & (US$ Million)

Table 41. Europe Antibody and Recombinant Protein CDMO Market Size by Application (2025-2030) & (US$ Million)

Table 42. Europe Antibody and Recombinant Protein CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 43. Europe Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024) & (US$ Million)

Table 44. Europe Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030) & (US$ Million)

Table 45. China Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024) & (US$ Million)

Table 46. China Antibody and Recombinant Protein CDMO Market Size by Type (2025-2030) & (US$ Million)

Table 47. China Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024) & (US$ Million)

Table 48. China Antibody and Recombinant Protein CDMO Market Size by Application (2025-2030) & (US$ Million)

Table 49. Asia Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024) & (US$ Million)

Table 50. Asia Antibody and Recombinant Protein CDMO Market Size by Type (2025-2030) & (US$ Million)

Table 51. Asia Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024) & (US$ Million)

Table 52. Asia Antibody and Recombinant Protein CDMO Market Size by Application (2025-2030) & (US$ Million)

Table 53. Asia Antibody and Recombinant Protein CDMO Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 54. Asia Antibody and Recombinant Protein CDMO Market Size by Region (2019-2024) & (US$ Million)

Table 55. Asia Antibody and Recombinant Protein CDMO Market Size by Region (2025-2030) & (US$ Million)

Table 56. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024) & (US$ Million)

Table 57. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Type (2025-2030) & (US$ Million)

Table 58. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Application (2025-2030) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 61. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024) & (US$ Million)

Table 62. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030) & (US$ Million)

Table 63. Batavia Biosciences Company Details

Table 64. Batavia Biosciences Business Overview

Table 65. Batavia Biosciences Antibody and Recombinant Protein CDMO Product

Table 66. Batavia Biosciences Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 67. Batavia Biosciences Recent Developments

Table 68. Grifols Company Details

Table 69. Grifols Business Overview

Table 70. Grifols Antibody and Recombinant Protein CDMO Product

Table 71. Grifols Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 72. Grifols Recent Developments

Table 73. Cerbios-Pharma SA Company Details

Table 74. Cerbios-Pharma SA Business Overview

Table 75. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product

Table 76. Cerbios-Pharma SA Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 77. Cerbios-Pharma SA Recent Developments

Table 78. HALIX Company Details

Table 79. HALIX Business Overview

Table 80. HALIX Antibody and Recombinant Protein CDMO Product

Table 81. HALIX Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 82. HALIX Recent Developments

Table 83. Biovian Oy Company Details

Table 84. Biovian Oy Business Overview

Table 85. Biovian Oy Antibody and Recombinant Protein CDMO Product

Table 86. Biovian Oy Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 87. Biovian Oy Recent Developments

Table 88. Catalent Company Details

Table 89. Catalent Business Overview

Table 90. Catalent Antibody and Recombinant Protein CDMO Product

Table 91. Catalent Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 92. Catalent Recent Developments

Table 93. Goodwin Biotechnology Company Details

Table 94. Goodwin Biotechnology Business Overview

Table 95. Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product

Table 96. Goodwin Biotechnology Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 97. Goodwin Biotechnology Recent Developments

Table 98. Merck Company Details

Table 99. Merck Business Overview

Table 100. Merck Antibody and Recombinant Protein CDMO Product

Table 101. Merck Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 102. Merck Recent Developments

Table 103. Hangzhou Hs-biopharm Company Details

Table 104. Hangzhou Hs-biopharm Business Overview

Table 105. Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product

Table 106. Hangzhou Hs-biopharm Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 107. Hangzhou Hs-biopharm Recent Developments

Table 108. Wuxibiologics Company Details

Table 109. Wuxibiologics Business Overview

Table 110. Wuxibiologics Antibody and Recombinant Protein CDMO Product

Table 111. Wuxibiologics Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 112. Wuxibiologics Recent Developments

Table 113. Bioinnobio Company Details

Table 114. Bioinnobio Business Overview

Table 115. Bioinnobio Antibody and Recombinant Protein CDMO Product

Table 116. Bioinnobio Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 117. Bioinnobio Recent Developments

Table 118. Thousand Oaks Biopharmaceuticals Company Details

Table 119. Thousand Oaks Biopharmaceuticals Business Overview

Table 120. Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product

Table 121. Thousand Oaks Biopharmaceuticals Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 122. Thousand Oaks Biopharmaceuticals Recent Developments

Table 123. Eurogentec Company Details

Table 124. Eurogentec Business Overview

Table 125. Eurogentec Antibody and Recombinant Protein CDMO Product

Table 126. Eurogentec Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 127. Eurogentec Recent Developments

Table 128. HJB Company Details

Table 129. HJB Business Overview

Table 130. HJB Antibody and Recombinant Protein CDMO Product

Table 131. HJB Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 132. HJB Recent Developments

Table 133. Bibo Pharma Company Details

Table 134. Bibo Pharma Business Overview

Table 135. Bibo Pharma Antibody and Recombinant Protein CDMO Product

Table 136. Bibo Pharma Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 137. Bibo Pharma Recent Developments

Table 138. MabPlex International Company Details

Table 139. MabPlex International Business Overview

Table 140. MabPlex International Antibody and Recombinant Protein CDMO Product

Table 141. MabPlex International Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 142. MabPlex International Recent Developments

Table 143. Genscriptprobio Company Details

Table 144. Genscriptprobio Business Overview

Table 145. Genscriptprobio Antibody and Recombinant Protein CDMO Product

Table 146. Genscriptprobio Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 147. Genscriptprobio Recent Developments

Table 148. Vetter Company Details

Table 149. Vetter Business Overview

Table 150. Vetter Antibody and Recombinant Protein CDMO Product

Table 151. Vetter Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 152. Vetter Recent Developments

Table 153. Etinpro (Beijing) Co Company Details

Table 154. Etinpro (Beijing) Co Business Overview

Table 155. Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product

Table 156. Etinpro (Beijing) Co Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 157. Etinpro (Beijing) Co Recent Developments

Table 158. Boehringer Ingelheim BioXcellence Company Details

Table 159. Boehringer Ingelheim BioXcellence Business Overview

Table 160. Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product

Table 161. Boehringer Ingelheim BioXcellence Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 162. Boehringer Ingelheim BioXcellence Recent Developments

Table 163. Lonza Company Details

Table 164. Lonza Business Overview

Table 165. Lonza Antibody and Recombinant Protein CDMO Product

Table 166. Lonza Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 167. Lonza Recent Developments

Table 168. 3SBio Inc Company Details

Table 169. 3SBio Inc Business Overview

Table 170. 3SBio Inc Antibody and Recombinant Protein CDMO Product

Table 171. 3SBio Inc Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 172. 3SBio Inc Recent Developments

Table 173. Porton Company Details

Table 174. Porton Business Overview

Table 175. Porton Antibody and Recombinant Protein CDMO Product

Table 176. Porton Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)

Table 177. Porton Recent Developments

Table 178. Research Programs/Design for This Report

Table 179. Key Data Information from Secondary Sources

Table 180. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Antibody and Recombinant Protein CDMO Market Share by Type: 2023 VS 2030

Figure 3. Antibody CDMO Features

Figure 4. Recombinant Protein CDMO Features

Figure 5. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 6. Global Antibody and Recombinant Protein CDMO Market Share by Application: 2023 VS 2030

Figure 7. Pharmaceutical Company Case Studies

Figure 8. Biotechnology Company Case Studies

Figure 9. Generic Company Case Studies

Figure 10. Antibody and Recombinant Protein CDMO Report Years Considered

Figure 11. Global Antibody and Recombinant Protein CDMO Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 12. Global Antibody and Recombinant Protein CDMO Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Antibody and Recombinant Protein CDMO Market Share by Region: 2023 VS 2030

Figure 14. Global Antibody and Recombinant Protein CDMO Market Share by Players in 2023

Figure 15. Global Top Antibody and Recombinant Protein CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody and Recombinant Protein CDMO as of 2023)

Figure 16. The Top 10 and 5 Players Market Share by Antibody and Recombinant Protein CDMO Revenue in 2023

Figure 17. North America Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 18. North America Antibody and Recombinant Protein CDMO Market Share by Type (2019-2030)

Figure 19. North America Antibody and Recombinant Protein CDMO Market Share by Application (2019-2030)

Figure 20. North America Antibody and Recombinant Protein CDMO Market Share by Country (2019-2030)

Figure 21. United States Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Antibody and Recombinant Protein CDMO Market Size YoY (2019-2030) & (US$ Million)

Figure 24. Europe Antibody and Recombinant Protein CDMO Market Share by Type (2019-2030)

Figure 25. Europe Antibody and Recombinant Protein CDMO Market Share by Application (2019-2030)

Figure 26. Europe Antibody and Recombinant Protein CDMO Market Share by Country (2019-2030)

Figure 27. Germany Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. France Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. U.K. Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Italy Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Russia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Nordic Countries Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. China Antibody and Recombinant Protein CDMO Market Size YoY (2019-2030) & (US$ Million)

Figure 34. China Antibody and Recombinant Protein CDMO Market Share by Type (2019-2030)

Figure 35. China Antibody and Recombinant Protein CDMO Market Share by Application (2019-2030)

Figure 36. Asia Antibody and Recombinant Protein CDMO Market Size YoY (2019-2030) & (US$ Million)

Figure 37. Asia Antibody and Recombinant Protein CDMO Market Share by Type (2019-2030)

Figure 38. Asia Antibody and Recombinant Protein CDMO Market Share by Application (2019-2030)

Figure 39. Asia Antibody and Recombinant Protein CDMO Market Share by Region (2019-2030)

Figure 40. Japan Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. South Korea Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. China Taiwan Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Southeast Asia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. India Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Australia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Size YoY (2019-2030) & (US$ Million)

Figure 47. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Share by Type (2019-2030)

Figure 48. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Share by Application (2019-2030)

Figure 49. Middle East, Africa, and Latin America Antibody and Recombinant Protein CDMO Market Share by Country (2019-2030)

Figure 50. Brazil Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 51. Mexico Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 52. Turkey Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 53. Saudi Arabia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 54. Israel Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 55. GCC Countries Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. Batavia Biosciences Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 57. Grifols Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 58. Cerbios-Pharma SA Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 59. HALIX Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 60. Biovian Oy Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 61. Catalent Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 62. Goodwin Biotechnology Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 63. Merck Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 64. Hangzhou Hs-biopharm Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 65. Wuxibiologics Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 66. Bioinnobio Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 67. Thousand Oaks Biopharmaceuticals Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 68. Eurogentec Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 69. HJB Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 70. Bibo Pharma Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 71. MabPlex International Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 72. Genscriptprobio Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 73. Vetter Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 74. Etinpro (Beijing) Co Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 75. Boehringer Ingelheim BioXcellence Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 76. Lonza Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 77. 3SBio Inc Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 78. Porton Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)

Figure 79. Bottom-up and Top-down Approaches for This Report

Figure 80. Data Triangulation

Figure 81. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What is the annual compound growth rate of the global Antibody and Recombinant Protein CDMO market size from 2024 to 2030? zhanKai

The annual compound growth rate of the global Antibody and Recombinant Protein CDMO market is 7% 2024 to 2030.

Which companies rank high in the global Antibody and Recombinant Protein CDMO market? shouQi

Which region is expected to have the highest market share? shouQi

What was the global market size of Antibody and Recombinant Protein CDMO in 2024? shouQi

What was the global market size of Antibody and Recombinant Protein CDMO in 2030? shouQi

Related Reports

Antibody and Recombinant Protein CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Antibody and Recombinant Protein CDMO was estimated to be worth US$ 59130 million in 2024 and is forecast to a readjusted size of US$ 94330 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 149
USD 3950.00
(Single User License)
Global Antibody and Recombinant Protein CDMO Market Research Report 2025
The global market for Antibody and Recombinant Protein CDMO was valued at US$ 59130 million in the year 2024 and is projected to reach a revised size of US$ 94330 million by 2031, growing at a CAGR of 7.0% during the forecast period.
Published Date: 2025-01-16
Pages: 105
USD 2900.00
(Single User License)
Global Antibody and Recombinant Protein CDMO Market Research Report 2024
The global Antibody and Recombinant Protein CDMO market was valued at US$ 51310 million in 2023 and is anticipated to reach US$ 83480 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
Published Date: 2024-01-12
Pages: 106
USD 2900.00
(Single User License)
Antibody and Recombinant Protein CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Antibody and Recombinant Protein CDMO was estimated to be worth US$ 51310 million in 2023 and is forecast to a readjusted size of US$ 83480 million by 2030 with a CAGR of 7.0% during the forecast period 2024-2030
Published Date: 2024-01-08
Pages: 156
USD 3950.00
(Single User License)

Antibody and Recombinant Protein CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Antibody and Recombinant Protein CDMO was estimated to be worth US$ 59130 million in 2024 and is forecast to a readjusted size of US$ 94330 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 149
USD 3950.00 (Single User License)
Global Antibody and Recombinant Protein CDMO Market Research Report 2025
The global market for Antibody and Recombinant Protein CDMO was valued at US$ 59130 million in the year 2024 and is projected to reach a revised size of US$ 94330 million by 2031, growing at a CAGR of 7.0% during the forecast period.
Published: 2025-01-16
Pages: 105
USD 2900.00 (Single User License)
Global Antibody and Recombinant Protein CDMO Market Research Report 2024
The global Antibody and Recombinant Protein CDMO market was valued at US$ 51310 million in 2023 and is anticipated to reach US$ 83480 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
Published: 2024-01-12
Pages: 106
USD 2900.00 (Single User License)
Antibody and Recombinant Protein CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Antibody and Recombinant Protein CDMO was estimated to be worth US$ 51310 million in 2023 and is forecast to a readjusted size of US$ 83480 million by 2030 with a CAGR of 7.0% during the forecast period 2024-2030
Published: 2024-01-08
Pages: 156
USD 3950.00 (Single User License)